Opinion|Videos|February 5, 2024
Treating Patients with Metastatic HER2+ Breast Cancer
Medical oncologists discuss the various treatment options for patients with metastatic HER2+ breast cancer and where they fit into the treatment algorithm.
Advertisement
Advertisement
Related to this article
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.
“What has changed is that we are bringing the phase 1 trials earlier in the course of treatment for our patients,” said Oana Danciu, MD.
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
3
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
4
ctDNA Is Prognostic Regardless of Therapy in Cisplatin-Eligible MIBC
5